With 0.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.37 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.7 whereas the lowest price it dropped to was $2.4. The 52-week range on PHIO shows that it touched its highest point at $9.79 and its lowest point at $0.97 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.88.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PHIO was up-trending over the past week, with a rise of 0.79%, but this was up by 17.05% over a month. Three-month performance surged to 18.69% while six-month performance rose 25.74%. The stock gained 41.11% in the past year, while it has lost -33.97% so far this year. A look at the trailing 12-month EPS for PHIO yields -6.51 with Next year EPS estimates of -0.83. For the next quarter, that number is -0.36. This implies an EPS growth rate of 82.60% for this year and 47.47% for next year. EPS is expected to grow by 64.39% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 66.30%.
Float and Shares Shorts:
At present, 4.78 million PHIO shares are outstanding with a float of 4.73 million shares on hand for trading. On 2025-07-15, short shares totaled 0.33 million, which was 686.0 higher than short shares on 1749772800. In addition to Mr. Robert J. Bitterman as the firm’s President, CEO & Chairman, Ms. Lisa Carson serves as its Principal Financial Officer, Principal Accounting Officer and VP of Finance & Administration.
Institutional Ownership:
Through their ownership of 0.15767999 of PHIO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, PHIO reported revenue of $0.0 and operating income of -$1872000.0. The EBITDA in the recently reported quarter was -$1872000.0 and diluted EPS was -$0.41.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With PHIO analysts setting a high price target of 14.0 and a low target of 14.0, the average target price over the next 12 months is 14.0. Based on these targets, PHIO could surge 451.18% to reach the target high and rise by 451.18% to reach the target low. Reaching the average price target will result in a growth of 451.18% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$8.54 being high and -$8.54 being low. For PHIO, this leads to a yearly average estimate of -$8.54. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
